ADVENTRX Pharmaceuticals, Inc. (ANX) said it has submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration for its product candidate ANX-530.
ANX-530 is ADVENTRX's proprietary emulsion formulation of vinorelbine.
The company is seeking approval of ANX-530 for the same indications as Navelbine, a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX submitted the NDA as a 505(b)(2) application, which relies in part on the FDA's findings of safety and effectiveness of a reference drug. The company's 505(b)(2) NDA submission includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of ANX 530 and Navelbine, the reference drug.
For comments and feedback: editorial@rttnews.com